- Home
- Weight Management & Metabolism
- Orforglipron
Weight Management
Orforglipron
Orforglipron · Oral small-molecule GLP‑1 receptor agonist
An oral, non-peptide GLP‑1 receptor agonist. Not a peptide.
- Partner pharmacy
- Personal assistance
- Discreet delivery
Shipping & Delivery
- Normally dispatched within 24 hours of payment confirmation.
- UPS Express · A$25 · Approx. 7–9 business days
- Registered Mail · A$15 · Approx. 14–20 business days
What is known so far
Orforglipron is an oral small-molecule (non-peptide) GLP‑1 receptor agonist developed for obesity and type 2 diabetes.
Its authorisation status in Australia is under review. This page is informational only and does not describe proven clinical benefits.
Product information
Patient information leafletNot available: authorisation status under review
Summary of Product CharacteristicsNot available: authorisation status under review
Sources
- US Food and Drug Administration. Novel Drug Approvals for 2026: Foundayo (orforglipron), 1 April 2026.
Related
Weight Management 
